Abstract

Non-Hodgkin Lymphomas are always treatable and frequently curable malignancies. However, choosing the most appropriate therapy requires accurate diagnosis and a careful staging evaluation. New patients with non-Hodgkin Lymphoma should have their tumors classified using the World Health Organization classification. The specific choice of therapy is dependent on a careful staging evaluation. Patients with non-Hodgkin Lymphoma are assigned an anatomic stage using the Ann Arbor system. However, patients should also be classified using the International Prognostic Index. New insights into the biology of the lymphomas in the coming years might well improve our ability to evaluate patients and choose therapy.

Original languageEnglish (US)
Pages (from-to)368-376
Number of pages9
JournalCa-A Cancer Journal for Clinicians
Volume55
Issue number6
DOIs
StatePublished - 2005

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Staging non-Hodgkin lymphoma'. Together they form a unique fingerprint.

  • Cite this